Rexahn Pharmaceuticals, Inc. Awarded U.S. Patent for Novel Anti-Cancer Compounds
6/17/2013 9:22:12 AM
More...
|
Rexahn Pharmaceuticals, Inc. to Present Data on the Mechanism of Action of RX-5902: a First-in-Class Inhibitor of p68 Helicase for the Treatment of Solid Tumors at American Association for Cancer Research Annual Meeting 2013
4/2/2013 9:54:31 AM
More...
|
Rexahn Pharmaceuticals, Inc. to Present at the 25th Annual ROTH Conference
3/11/2013 6:15:29 AM
More...
|
Rexahn Pharmaceuticals, Inc. Provides Key Goals for 2013
2/19/2013 9:34:30 AM
More...
|
Rexahn Pharmaceuticals, Inc. Appoints Peter D. Suzdak as CEO
1/22/2013 7:38:34 AM
More...
|
Rexahn Pharmaceuticals, Inc. Expands its Intellectual Property Around Class of Potent Anti-cancer Isoquinolinamine Compounds
12/17/2012 9:49:59 AM
More...
|
Rexahn Pharmaceuticals, Inc. Closes Public Offering for $6,600,000 in Gross Proceeds
12/5/2012 10:50:08 AM
More...
|
Rexahn Pharmaceuticals, Inc. Prices Public Offering of Stock
11/29/2012 9:31:56 AM
More...
|
Rexahn Pharmaceuticals, Inc. Issued U.S. Patent for Quinoxalinyl-piperazine Compounds
11/21/2012 10:50:55 AM
More...
|
Rexahn Pharmaceuticals, Inc. Granted European Patent for Novel Anti-cancer Isoquinolinamine Compounds
9/26/2012 9:31:09 AM
More...
|
|